SCHEMBL7864515

SCHEMBL7864515

COc1c(-c2ccc(SC)cc2)c(-c2ccc(F)cc2)n[nH]c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK13 O15264 5/20 0.42
MAPK12 P53778 5/20 0.42
MAPK11 Q15759 5/20 0.42
MAPK14 Q16539 5/20 0.42
GCGR P47871 4/20 0.42
PRKD3 O94806 1/20 0.42
MAP4K4 O95819 1/20 0.42
LCK P06239 1/20 0.42
RET P07949 1/20 0.42
ALOX5 P09917 1/20 0.42
PRKACA P17612 1/20 0.42
RPS6KB1 P23443 1/20 0.42
MATK P42679 1/20 0.42
FRK P42685 1/20 0.42
MAPK9 P45984 1/20 0.42
CSNK1A1 P48729 1/20 0.42
CSNK1D P48730 1/20 0.42
GSK3A P49840 1/20 0.42
GSK3B P49841 1/20 0.42
CSNK1G2 P78368 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7777792 0.74 GYS1 (0.54) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL3939765 0.71 MAPK14 (0.45) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL4183686 0.71 PTGS1 (0.43) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL11285169 0.69 KMT2A (0.73) MAPK11MAPK14ALPLMEN1KMT2A
SCHEMBL7773094 0.68 PTGS1 (0.49) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL11168349 0.68 ALPL (0.46) MAPK11MAPK14ALPLMEN1KMT2A
SCHEMBL6440359 0.67 ALDH1A1 (0.41) MAPK13MAPK12MAPK11MAPK14GCGR
SCHEMBL20074684 0.66 ALDH1A1 (0.45) ALPLMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL7527869 0.66 PTGS2 (0.46) ALOX5PTGS2PTGS1
SCHEMBL2374242 0.66 ALDH1A1 (0.45) MAPK13MAPK12MAPK11MAPK14GCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6307047-B1 PYRIDAZINONE COMPOUNDS; INHIBITORS OF CYCLOOXYGENASE-2 (COX-2); SELECTIVITY OF THESE COMPOUNDS FOR COX-2 MINIMIZES THE UNWANTED GI AND RENAL SIDE-EFFECTS SEEN WITH CURRENTLY MARKETED NON-STEROIDAL ANTI-INFLAMMATORY DRUGS ABBOTT LABORATORIES 2001-10-23 US disclosed